- |||||||||| PF-06412562 / Pfizer, Cerevel Therap
Journal: Dopamine D Agonists: First Potential Treatment for Late-Stage Parkinson's Disease. (Pubmed Central) - May 31, 2023
These data suggest for the first time that there can be useful pharmacological intervention in LsPD patients using D agonists and also that caregiver perspectives with mixed method analyses may overcome limitations using methods common in early-stage patients. The results encourage future clinical studies and understanding of the most efficacious signaling properties of a D agonist for this population.
- |||||||||| Treatment of chorea in NXK2-1-related disorders: A Systematic Review (Foyer 3B, 3rd Floor) - May 29, 2023 - Abstract #EPNS2023EPNS_626;
The percentage of patients treated with methylphenidate who experience improvement in chorea is greater than that of patients treated with other medications. However, due to poor methodological quality, additional treatment studies may be required to recommend therapeutic options.
- |||||||||| carbidopa/levodopa / Generic mfg., gabapentin / Generic mfg.
A Case of Gambling Disorder and Impulsivity During the Treatment of Restless Leg Syndrome (Hall B Foyer, Exhibition Level Moscone South) - May 17, 2023 - Abstract #APA2023APA_800;
As per the literature, it is well known that dopamine agonist therapy can induce GD which is characterized by the failure to resist gambling impulses despite severe personal, family, or occupational consequences resulting in reduced quality of life. In this case report, we hope to increase awareness of the potential relationship between dopamine agonist therapy and rare but serious side effects such as impulsive behavior and GD.
- |||||||||| Comtan (entacapone) / Novartis, Orion Corp
Journal: Apprends-moi l'art des petits pas: Levodopa, Carbidopa Intestinal Gel plus Entacapone. (Pubmed Central) - Apr 28, 2023
This study is a prospective non-interventional study of the long-term effectiveness and safety of levodopa-entacapone-carbidopa intestinal gel (LECIG) in patients with aPD in routine care. This observational study is designed to collect data on the use of the drug Lecigon
- |||||||||| carbidopa/levodopa / Generic mfg.
Journal: The Importance of Dopamine Deficiency Evaluation in Non-Alzheimer Disease Dementias. (Pubmed Central) - Apr 5, 2023
All patients received treatment with carbidopa/levodopa and demonstrated improved overall function...Thus, a DAT scan is critical for establishing an earlier and more definitive diagnosis of DLB, which provides treatment options for dopamine replacement. It also assists providers with prognostication of dopamine deficiency syndromes and is therefore beneficial in counseling patients and caregivers.
- |||||||||| foscarbidopa/foslevodopa (ABBV-951) / AbbVie
PK/PD data, Journal: Comparability of Foslevodopa/Foscarbidopa Pharmacokinetics in Healthy Asian and White Participants. (Pubmed Central) - Apr 4, 2023
The regimens tested were generally well tolerated, and no new safety issues were identified in this study. There were no clinically meaningful differences in LD and CD exposures or pharmacokinetics following administration of foslevodopa/foscarbidopa among White, Japanese, and Han Chinese participants.
- |||||||||| Inbrija (levodopa inhalation powder) / Acorda
Journal: The Clinical Development of Levodopa Inhalation Powder. (Pubmed Central) - Mar 15, 2023
Levodopa inhalation powder 84 mg increased plasma levodopa concentration rapidly and with less variability than oral levodopa/carbidopa (25/100 mg). Most common adverse event associated with levodopa inhalation powder is cough, found in ~15% of patients in the SPAN-PD trial; otherwise, reported adverse events were consistent with those known to be associated with oral levodopa.
- |||||||||| Enrollment change: Dopaminergic Dysfunction in Late-Life Depression (clinicaltrials.gov) - Mar 14, 2023
P2, N=80, Recruiting,
These changes translated into higher trough concentrations and decreased peak-to-trough fluctuations for LD. N=60 --> 80
- |||||||||| carbidopa/levodopa / Generic mfg.
Vertical supranuclear gaze palsy in Primary Familial Brain Calcification associated with a novel SLC20A2 mutation (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_4294;
Background OPC is a once-daily COMT inhibitor approved as adjunctive treatment to carbidopa/levodopa (CD/LD) in patients with Parkinson Results This 74-year-old Chinese woman with a negative relevant family history presented with a six-year history of parkinsonism, frequent falls, speech disturbances and VSGP on examination that failed to respond to levodopa/carbidopa.
- |||||||||| carbidopa/levodopa / Generic mfg., rivastigmine / Generic mfg.
Spinocerebellar ataxia 21 and phenotypic variability within a single family (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_3280;
The father underwent treatment for parkinsonism with carbidopa-levodopa and was started on rivastigmine without improvement. Conclusions SCA21 is a slowly progressive autosomal dominant spinocerebellar ataxia with variable neurodevelopmental phenotypes including multiple movement disorders within the same variant.
- |||||||||| Ongentys (opicapone) / Ono Pharma, Neurocrine, BIAL
Patients Reported Improvement in Quality of (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_3126;
Conclusions SCA21 is a slowly progressive autosomal dominant spinocerebellar ataxia with variable neurodevelopmental phenotypes including multiple movement disorders within the same variant. Background Opicapone is an oral, once-daily, selective catechol-O-methyltransferase (COMT) inhibitor used as adjunctive treatment to carbidopa/levodopa (CD/LD) in patients with Parkinson
- |||||||||| amantadine / Generic mfg.
Retrospective Review of Amantadine Use in Progressive Supranuclear Palsy (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_2935;
Adverse effects included confusion/hallucinations (6), worsening gait/dizziness (3), and leg edema (1). Conclusions While a small percentage of PSP patients tolerated and reported subjective benefit from amantadine, objectively, amantadine did not improve PSPRS scores and may worsen symptoms or cause adverse effects.
- |||||||||| Triolex (NE3107) / BioVie
Safety, Tolerability, And Efficacy Of NE3107 From A Phase 2, Double-Blind, Placebo-Controlled Study In Levodopa/Carbidopa-Treated Patients With Parkinson's Disease (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_1308;
Results Outcomes of the efficacy, safety, and tolerability analyses will be presented at the conference. Conclusions Using safety, tolerability, and efficacy analyses, this study aimed to demonstrate the potential therapeutic benefits of NE3107 in levodopa/carbidopa-treated patients with PD.
- |||||||||| Ongentys (opicapone) / Ono Pharma, Neurocrine, BIAL
Patient-Reported Improvements in () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_1169;
Conclusions Using safety, tolerability, and efficacy analyses, this study aimed to demonstrate the potential therapeutic benefits of NE3107 in levodopa/carbidopa-treated patients with PD. OBJECTIVES: Opicapone is an oral, once-daily, selective catechol-O-methyltransferase (COMT) inhibitor, approved as an adjunctive treatment to levodopa/carbidopa (LD/CD) in patients with Parkinson
- |||||||||| carbidopa/levodopa / Generic mfg.
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date: Research on Translational Outcomes of Alcohol (Project RETRO) (clinicaltrials.gov) - Feb 13, 2023
P4, N=0, Withdrawn,
The AUC for levodopa/carbidopa multiparticulate matrix (Formulation 3: 484.98 N=42 --> 0 | Trial completion date: Dec 2021 --> Aug 2023 | Not yet recruiting --> Withdrawn | Trial primary completion date: Dec 2021 --> Aug 2023
- |||||||||| Rytary (levodopa/carbidopa extended-release capsule) / Amneal
Trial completion date, Trial primary completion date: Novel Non-opioid Post-surgical Pain Treatment in Females (clinicaltrials.gov) - Feb 8, 2023
P2, N=60, Recruiting,
N=42 --> 0 | Trial completion date: Dec 2021 --> Aug 2023 | Not yet recruiting --> Withdrawn | Trial primary completion date: Dec 2021 --> Aug 2023 Trial completion date: Jan 2023 --> Jan 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
- |||||||||| carbidopa/levodopa / Generic mfg.
Review, Journal: Does Drinking Coffee Reduce the Incidence of Parkinson's Disease? (Pubmed Central) - Feb 2, 2023
Although there is strong evidence that caffeine is neuroprotective, there is less evidence that it delays the onset of PD. Given the association with cardiovascular disease, it may be disadvantageous overall to the majority of the population to supplement caffeine, though still a beneficial preventative technique for individuals with a genetic predisposition to PD that may otherwise suffer early onset.
- |||||||||| Trial initiation date: The Role of Brain Dopamine in Chronic Pain (clinicaltrials.gov) - Jan 11, 2023
P2, N=10, Recruiting,
Given the association with cardiovascular disease, it may be disadvantageous overall to the majority of the population to supplement caffeine, though still a beneficial preventative technique for individuals with a genetic predisposition to PD that may otherwise suffer early onset. Initiation date: Oct 2022 --> Jan 2023
- |||||||||| Trial completion date, Trial primary completion date: Gait Analysis in Neurological Disease (clinicaltrials.gov) - Jan 4, 2023
P=N/A, N=120, Active, not recruiting,
Initiation date: Oct 2022 --> Jan 2023 Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Jun 2023 --> Jun 2024
- |||||||||| Kynmobi (apomorphine sublingual film) / Sumitomo Dainippon, Aquestive, BIAL
Journal: Motor response with apomorphine sublingual film and levodopa in patients with OFF episodes. (Pubmed Central) - Dec 24, 2022
Following an optimized SL-APO dose, mean improvements in MDS-UPDRS-III scores were -13.9 and -22.9, and FULL ON was achieved by 34.7 and 81.0% of patients. Concomitant administration of SL-APO with carbidopa/levodopa may be useful for delayed ON.
- |||||||||| Triolex (NE3107) / BioVie
SAFETY, TOLERABILITY, AND EFFICACY OF NE3107 FROM A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY IN LEVODOPA/CARBIDOPA-TREATED PATIENTS WITH PARKINSON'S DISEASE (ONSITE - HALL F1+F2+F3) - Dec 23, 2022 - Abstract #ADPD2023ADPD_882;
Results Outcomes of the efficacy, safety, and tolerability analyses will be presented at the conference. Conclusions Using safety, tolerability, and efficacy analyses, this study aimed to demonstrate the potential therapeutic benefits of NE3107 in levodopa/carbidopa-treated patients with PD.
- |||||||||| Nuplazid (pimavanserin) / Acadia Pharma
TREATING DLB: CURRENT PRACTICE AND FUTURE DIRECTIONS (ONSITE - HALL F1+F2+F3) - Dec 23, 2022 - Abstract #ADPD2023ADPD_878;
burden once it's detected either by PET imaging or CSF/blood assays. According to this formulation, countering the toxic effects of excessive amyloid burden should be neuroprotective and moderate disease progression.
- |||||||||| carbidopa/levodopa / Generic mfg., levodopa/carbidopa orally disintegrating tablets / Generic mfg.
Trial completion date, Trial primary completion date: Vigor and the LDR in Parkinson Disease (clinicaltrials.gov) - Dec 5, 2022
P=N/A, N=40, Recruiting,
It is important for clinicians to keep this in mind, since LUTI is a leading cause of hospitalizations, morbidity, and mortality in patients with PD. Trial completion date: Feb 2023 --> Feb 2024 | Trial primary completion date: Feb 2023 --> Feb 2024
- |||||||||| carbidopa/levodopa / Generic mfg.
Journal: Comprehensibility of a personalized medication overview compared to usual-care prescription drug labels. (Pubmed Central) - Nov 18, 2022
Outcome measures included comprehension of instructions for medication use, e.g. how often, dose timing, usage advice and warnings for a medication with simple use instructions (omeprazol) and more complex use instructions (levodopa/carbidopa (L/C))...As a medication overview contains additional information, it can be a good addition in supporting patients in their medication use compared to usual-care PDLs. Future research should focus on identifying patient groups who might benefit more from a medication overview, by testing the effect of such overview on this group.
- |||||||||| Ongentys (opicapone) / Ono Pharma, Neurocrine, BIAL
PK/PD data, Journal: Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease. (Pubmed Central) - Nov 16, 2022
Combining opicapone 50 mg with a 100 mg lower daily dose of levodopa provides higher levodopa bioavailability with avoidance of trough levels. Despite the lower levodopa dose, modifying the levodopa pharmacokinetic profile with opicapone was associated with decreased off time and increased on time.
|
